IDT AustraliaASX:IDT PB Ratio is 0.69 as of Jun. 26, 2026, which is 43% below its 10-year median of 1.20. The stock has 6 warning signs investors should review. Among 922 Drug Manufacturers companies, IDT Australia ranks better than 86.23% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), IDT Australia's share price is A$0.033. IDT Australia's Book Value per Share for the quarter that ended in Dec. 2025 was A$0.05. Hence, IDT Australia's PB Ratio of today is 0.69.
Good Sign:
IDT Australia Ltd stock PB Ratio (=0.71) is close to 2-year low of 0.67.
The historical rank and industry rank for IDT Australia's PB Ratio or its related term are showing as below:
ASX:IDT'
s PB Ratio Range Over the Past 10 Years
Min: 0.35 Med: 1.2 Max: 6.48
Current: 0.69
During the past 13 years, IDT Australia's highest PB Ratio was 6.48. The lowest was 0.35. And the median was 1.20.
ASX:IDT's PB Ratio is ranked better than 86.23% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.825
vs ASX:IDT: 0.69
During the past 12 months, IDT Australia's average Book Value Per Share Growth Rate was -22.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -22.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -13.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -12.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of IDT Australia was 31.70% per year. The lowest was -30.70% per year. And the median was 2.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
IDT Australia PB Ratio Related Terms
IDT Australia PB Ratio Historical Data
* Premium members only.
The historical data trend for IDT Australia's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, IDT Australia's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDT Australia PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, IDT Australia's PB Ratio distribution charts can be found below:
* The bar in red indicates where IDT Australia's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
IDT Australia's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
IDT Australia (ASX:IDT) has a PB Ratio of 0.69 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on IDT Australia and its competitors. This is 43% below median its historical median of 1.20. Over the past decade, IDT Australia's PB Ratio has ranged from 0.35 to 6.48. According to the industry distribution chart, IDT Australia ranks #127 out of 922 companies in the Drug Manufacturers industry, placing it in the top 13.8%.
Is IDT Australia's PB Ratio too high?
IDT Australia's current PB Ratio of 0.69 is 43% below median its 10-year median of 1.20. Over the past 10 years, this metric has ranged from a low of 0.35 to a high of 6.48. The Drug Manufacturers industry median PB Ratio is 1.83. IDT Australia's value of 0.69 is 62.2% below this industry median. Based on the distribution chart, IDT Australia ranks #127 out of 922 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does IDT Australia's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, IDT Australia ranks #127 out of 922 companies for PB Ratio. This places IDT Australia in the top 14% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.83. IDT Australia's value of 0.69 is 62.2% below this benchmark. Historically, IDT Australia's own PB Ratio has ranged from 0.35 to 6.48 over the past decade. While the company's 10-year median is 1.20 vs. the industry median of 1.83, IDT Australia has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.83, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDT Australia's current PB Ratio of 0.69 is 62.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on IDT Australia and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDT Australia's current PB Ratio is 0.69, which is 43% below median its own 10-year median of 1.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDT Australia stock overvalued right now?
Based on GuruFocus' analysis, IDT Australia (ASX:IDT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.17, compared to a current price of A$0.03 — trading 80.6% below its estimated fair value. The current PB Ratio is 0.69, which is 43% below median its 10-year median of 1.20 and 62.2% below the Drug Manufacturers industry median of 1.83. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For IDT Australia (ASX:IDT), the current PB Ratio is 0.69 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
IDT Australia Ltd produces, develops, and supplies pharmaceutical products. It is engaged in the provision of research and development and other technical services for the pharmaceutical and allied industries. The company is involved in the manufacture of Active Pharmaceutical Ingredients (API) and Finished Dose Forms (FDF), microbiological and analytical testing, clinical packaging, and pharmacy services. The company operates in Australia, Asia, Europe, and the USA.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IDT has been successfully added to your 